论文部分内容阅读
目的哮喘和慢性阻塞性肺疾病(COPD)均为呼吸科常见病,两者可相互转换,分析布地奈德及氟替卡松联合治疗哮喘—慢性阻塞性肺疾病重叠综合征(ACOS)的治疗效果。方法选取广东省普宁市流沙大道普宁华侨医院2012年1月—2017年1月收治的118例ACOS患者,随机分为对照组和观察组,每组59例。对照组予以布地奈德进行治疗,观察组予以布地奈德联合氟替卡松进行治疗。比较两组治疗前及治疗后4个月1秒用力呼气量(FEV1)、FEV1预测值、用力呼气量占用力肺活量比值(FEV1/FVC)、不良反应、病情发作次数及发作间隔时间。结果治疗前,两组FEV1、FEV1预测值、FEV1/FVC比较,差异均无统计学意义(P>0.05);治疗后,观察组FEV1、FEV1预测值、FEV1/FVC高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组病情发作次数均少于本组治疗前及对照组治疗后,发作时间间隔治疗期间均长于本组治疗前及对照组治疗后,差异均有统计学意义(P<0.05)。对照组不良反应发生率为3.39%,观察组为6.78%,两组比较差异无统计学意义(χ2=0.281 3,P>0.05)。结论布地奈德联合氟替卡松治疗ACOS疗效较好,能提高患者肺功能,明显缓解患者临床症状。
Objectives Both asthma and chronic obstructive pulmonary disease (COPD) are common respiratory diseases, and the two can be switched to each other to analyze the therapeutic effect of budesonide combined with fluticasone in the treatment of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS). Methods A total of 118 ACOS patients admitted to Puning Overseas Chinese Hospital, Puning City, Puning City, Puning from January 2012 to January 2017 were randomly divided into control group and observation group, 59 cases in each group. The control group was treated with budesonide, and the observation group was treated with budesonide combined with fluticasone. The forced expiratory volume (FEV1), FEV1 predictive value, forced expiratory volume vital capacity (FEV1 / FVC), adverse reactions, the number of seizures and the interval between before treatment and 4 months after treatment were compared between the two groups. Results Before treatment, there was no significant difference in FEV1, FEV1 and FEV1 / FVC between the two groups (P> 0.05). After treatment, the FEV1 and FEV1 predictive values and FEV1 / FVC in the observation group were higher than those in the control group Statistical significance (P <0.05). After treatment, the number of attacks in the observation group were less than those in the control group before treatment and after treatment in the control group, and the duration of the attack interval was longer than that in the control group before treatment and in the control group (P <0.05). The incidence of adverse reactions in the control group was 3.39%, and the observation group was 6.78%. There was no significant difference between the two groups (χ2 = 0.281 3, P> 0.05). Conclusion Budesonide combined with fluticasone in the treatment of ACOS better effect, can improve lung function, significantly alleviate the clinical symptoms.